Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platform development, has announced its participation in the TD Cowen 45th Annual Healthcare Conference. The company's management will engage in a fireside chat on March 3, 2025, at 1:50 p.m. Eastern Time.
Investors and interested parties can access both live and archived webcasts of the presentation through the 'Investors' section of www.nautilus.bio. This participation demonstrates Nautilus' continued engagement with the investment community and healthcare sector.
Nautilus Biotechnology (NASDAQ: NAUT), un pioniere nello sviluppo di piattaforme per l'analisi delle proteine a singola molecola, ha annunciato la sua partecipazione alla 45a Conferenza Annuale sulla Salute di TD Cowen. La direzione dell'azienda parteciperà a una chiacchierata informale il 3 marzo 2025, alle 13:50 ora dell'Est.
Investitori e parti interessate possono accedere sia alle webcast in diretta che a quelle archiviate della presentazione attraverso la sezione 'Investitori' di www.nautilus.bio. Questa partecipazione dimostra l'impegno continuo di Nautilus con la comunità degli investitori e il settore sanitario.
Nautilus Biotechnology (NASDAQ: NAUT), un pionero en el desarrollo de plataformas para el análisis de proteínas a nivel de molécula única, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. La dirección de la empresa participará en una charla informal el 3 de marzo de 2025, a la 1:50 p.m. hora del Este.
Los inversores y partes interesadas pueden acceder tanto a las transmisiones en vivo como a las archivadas de la presentación a través de la sección 'Inversores' de www.nautilus.bio. Esta participación demuestra el compromiso continuo de Nautilus con la comunidad inversora y el sector de la salud.
나틸러스 생명공학 (NASDAQ: NAUT), 단일 분자 단백질 분석 플랫폼 개발의 선구자로, TD Cowen 제45회 연례 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사 경영진은 2025년 3월 3일 오후 1시 50분 동부 표준시에 화상 대담을 진행할 예정입니다.
투자자 및 관심 있는 당사자는 www.nautilus.bio의 '투자자' 섹션을 통해 발표의 실시간 및 아카이브 웹캐스트에 접근할 수 있습니다. 이번 참여는 나틸러스가 투자 커뮤니티 및 헬스케어 분야와 지속적으로 소통하고 있음을 보여줍니다.
Nautilus Biotechnology (NASDAQ: NAUT), un pionnier dans le développement de plateformes d'analyse de protéines à molécule unique, a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. La direction de l'entreprise participera à une discussion informelle le 3 mars 2025 à 13h50, heure de l'Est.
Les investisseurs et les parties intéressées peuvent accéder aux webcasts en direct et archivés de la présentation via la section 'Investisseurs' de www.nautilus.bio. Cette participation démontre l'engagement continu de Nautilus envers la communauté des investisseurs et le secteur de la santé.
Nautilus Biotechnology (NASDAQ: NAUT), ein Pionier in der Entwicklung von Plattformen zur Analyse von Einzelmolekül-Proteinen, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Das Management des Unternehmens wird am 3. März 2025 um 13:50 Uhr Eastern Time an einem informellen Gespräch teilnehmen.
Investoren und interessierte Parteien können sowohl auf die Live- als auch auf die archivierten Webcasts der Präsentation über den Bereich 'Investoren' auf www.nautilus.bio zugreifen. Diese Teilnahme zeigt das fortwährende Engagement von Nautilus gegenüber der Investoren-Community und dem Gesundheitssektor.
- None.
- None.
SEATTLE, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the TD Cowen 45th Annual Healthcare Conference.
Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 3, 2025, at 1:50 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
FAQ
When is Nautilus Biotechnology (NAUT) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch Nautilus Biotechnology's TD Cowen Conference presentation?
What type of presentation will NAUT deliver at the TD Cowen Healthcare Conference?
Which healthcare conference is Nautilus Biotechnology (NAUT) attending in March 2025?
